MMD LICENSES TWO MERCK DRUGS
In line with its strategy to refocus its research and licensing efforts toward products in later stages of development, Marion Merrell Dow has signed an agreement with Merck & Co obtaining rights to develop and market two cardiovascular compounds.
The first is a combination, once-daily formulation of diltiazem malate and enalapril, which is being developed in Phase III trials as a second-line therapy for hypertensive patients in whom single-drug therapy is inappropriate. The second is an extended-release formulation of diltiazem malate, which is also in Phase III trials. Merck says it licensed the drugs to MMD so it could concentrate on other programs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze